Clinical Study to Assess the Performance of the Dialyzer With Endexo™
An Open-Label Clinical Study to Assess the Performance of the Dialyzer With Endexo™ in End-Stage Renal Disease Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Chula Vista, California, United States, 92154
- Balboa Nephrology Med Group
-
San Diego, California, United States, 92111
- California Institute of Renal Research
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Research Management Inc/ Kansas Nephrology Research Institute, LLC-J/V
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be an adult, older than 22 years of age.
- Has been prescribed in-center thrice-weekly HD continuously for at least 180 days prior to the date of signed informed consent
- Has been prescribed the Optiflux F160NR dialyzer continuously for at least 30 days prior to the date of signed informed consent
- Has a prescribed HD treatment time ≥180 minutes (3 hours) and ≤270 minutes (4.5 hours)
- Has been on heparin anticoagulation for dialysis and has had no change in heparin prescription within 14 days prior to the date of signed informed consent
- Has a most recent single pool Kt/V (spKt/V) ≥1.2 within 45 days prior to the date of a signed informed consent
- Has a most recent hemoglobin ≥9 g/dL within 45 days prior to the date of a signed informed consent
- Has a most recent platelet count ≥100,000/mm3 within 45 days prior to the date of a signed informed consent
- A female of childbearing potential must have a negative serum pregnancy test at the time of screening and agree to use an acceptable method of contraception during the study
Exclusion Criteria:
- Use of citric acid concentrate (such as Citrasate®) at the time of signed informed consent
- Known allergic reactions to Endexo
- Hospitalization within 30 days prior to the date of signed informed consent
- Presence of active malignancy, congestive heart failure New York Heart Association (NYHA) Class III or IV, or liver cirrhosis
- Are receiving or have received chemotherapy / radiation therapy / plasmapheresis therapy within 90 days prior to the date of signed informed consent
- Are receiving antibiotics or have used antibiotics within 14 days prior to the date of signed informed consent
- Are currently enrolled in or have completed any other investigational product study within 30 days prior to the date of signed informed consent
- Has a life expectancy of less than 1 year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Optiflux/Endexo
Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
|
Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50.
Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance of the Dialyzer With Endexo by Measuring Its in Vivo Ultrafiltration Coefficient
Time Frame: 15 minutes after the recorded start of hemodialysis with Endexo upon its first use in the study
|
Ultrafiltration coefficient (Kuf) is the ratio of ultrafiltration rate in ml/hr to the Transmembrane pressure in mmHg.
Both the Ultrafiltration rate and the transmembrane pressure readings are collected from the machine.
|
15 minutes after the recorded start of hemodialysis with Endexo upon its first use in the study
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Number of Any Adverse Events
Time Frame: Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.
|
All adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.
|
Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.
|
|
The Number of Any Device-related Adverse Events
Time Frame: Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.
|
Any device-related adverse events were captured from subject enrollment to the completion of Optiflux period, and to the end of study or withdraws from the study.
|
Optiflux: from enrollment, weeks 1 to 4 (visits 1 to 12); Endexo: from weeks 5 to 17, and follow-up, a total of 17 weeks intervention.
|
|
Removal of Urea
Time Frame: At visits 1/week 1, 10/week 4, 13/week 5, 22/week 8, 34/week 12, and 46/week 16
|
|
At visits 1/week 1, 10/week 4, 13/week 5, 22/week 8, 34/week 12, and 46/week 16
|
|
Removal of Albumin
Time Frame: Pre- and Post- HD at Visits 1/week 1, 13/week 5
|
%change = (post-HD - pre-HD)/pre-HD * 100
|
Pre- and Post- HD at Visits 1/week 1, 13/week 5
|
|
Removal of Beta-2-microglobulin
Time Frame: Pre- and Post- HD at Visits 1/week 1, 13/week 5
|
% reduction = (post-HD - pre-HD)/pre-HD * 100 with post-HD B2M adjusted to pre- and post HD weights
|
Pre- and Post- HD at Visits 1/week 1, 13/week 5
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dialyzer Hemocompatibility
Time Frame: Assessed at the first time the dialyzers are used in the study , collected pre hemodialysis and 30 minutes after the recorded start of hemodialysis
|
The dialyzer hemo-compatibility is measured by measuring the activation of the complement system (C3a, C5a, SC5b-9)
|
Assessed at the first time the dialyzers are used in the study , collected pre hemodialysis and 30 minutes after the recorded start of hemodialysis
|
|
Clotting of the Dialyzer
Time Frame: visual evaluation of the dialyzer arterial cap will be performed at the end of every hemodialysis treatment to determine the Grade:1,2,3 or 4. (1:no clotting to 4: total clotting), throughout a total of 17 weeks intervention.
|
Thrombus scoring will be assessed according to a clotting scale (The graded scoring method)
|
visual evaluation of the dialyzer arterial cap will be performed at the end of every hemodialysis treatment to determine the Grade:1,2,3 or 4. (1:no clotting to 4: total clotting), throughout a total of 17 weeks intervention.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Shakil Aslam, MD, Fresenius Medical Care RTG, LLC
- Principal Investigator: Dylan Steer, MD, California Institute of Renal Research
- Principal Investigator: Lisa Weber, MD, Research Management Inc/ Kansas Nephrology Research Institute, LLC-J/V
- Principal Investigator: Jill Meyer, MD, Balboa Nephrology Med Group
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Endexo-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.